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Abstract 
BACKGROUND: Inflammation that occurred in the tumor microenvironment was characterized by abundant 
macrophage infiltration, playing role in innate immunity. Multinucleate giant cells (MGCs) occur in a variety of 
inflammatory, hyperplastic, and neoplastic thyroid disorders. They also have been recognized as a feature of 
papillary thyroid carcinoma (PTC). 
AIM: The aim of this study was to evaluate cases of PTC for the presence of macrophages, and estimate CD68+ 
TAMs density in tumor stroma, margin and the surrounding tissue. We assessed also MGCs.  
METHODS: Macrophages and MGCs densities were correlated with clinicopathologic parameters to assess the 
possible prognostic significance. We investigated 56 patients immunohistochemically and immunofluorescence 
with antibodies against CD68 and IL-17. 
RESULTS: A statistically significant correlation was established between PTC patients in III stage, containing 
many MGCs, and PTC in I and II stage, with many MGCs. Eighty Percent of patients in III stage showed many 
MGCs in comparison with patients in I and II stage, where many MGCs were found only in 21,1% (χ2 = 6.189, p = 
0.013). 
CONCLUSION: Our study demonstrates that the increased density of MGCs is associated with advanced stage 
of PTC, and therefore with tumor progression and that cases of PTC should be carefully screened for their 
presence. 
 
 
 
 
 
Introduction 
 
Papillary thyroid carcinoma (PTC) accounts 
for 80% of the thyroid malignancy that is characterized 
by slow growth and an excellent prognosis. However 
10-15% of cases exhibit aggressive behavior 
treatment resistance, and mobility [1], [2]. PTC is 
frequently associated with immune cell infiltration 
including lymphocyte dendritic cell and macrophage 
recruitment [3], [4], [5]. Macrophages have been 
categorized, into two subtypes – M1 and M2 – 
depending on their distinctive roles [6], [7]. Cancer 
cells recruit monocytes/macrophages from circulation. 
The main function of M1 macrophages is 
phagocytosis in response to LPS and/or T helper 
(Th1) cytokines such as IFN-γ. M1 macrophages are 
characterized by the production of pro-inflammatory 
cytokines (TNF-α, IL-6 and IL-12) and the induction of 
NOS [8]. In contrast the main function of M2 
macrophages is immunosuppression and trophic 
activity in response to Th2 cytokines (after exposure 
to IL-4 or IL-13), [6], [8], [9]. M2 macrophages or 
TAMs have anti- inflammatory properties. In addition 
M2 TAMs produce anti- inflammatory cytokines such 
as IL-10 and TGFβ1 [10], [11]. TGFβ1 regulates M2 
phenotype of macrophages and modulates their 
connections with other immune cell, like T cells [8] to 
tumor that dampen the immune response [11], [12]. 
Ryder et al., 2008 [13], investigated TAMs in 90 
patients with WDTC and PDTC and found that 
increased macrophages number was associated with 
extrathyroidal extension, capsular invasion and 
decreased cancer-related survival for PDTC. The 
same authors experimentally demonstrated that 
increased TAMs number promote PTC progression 
[13]. Other investigations [14] showed that in WDTC 
(mostly PTC) increased TAMs matched more 
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aggressive case with metastases at diagnosis; 
however paradoxically macrophage infiltration was 
associated with improved disease –free survival[14]. 
The morphology of TAMs in PTC, e.g., their canopy 
structure and their high density were connected with 
larger tumor size [4], suggesting a tumorigenic role of 
macrophages. That was associated with tumor 
dissemination in the regional lymph nodes [15]. 
Interleukin (IL)-17A, a signature cytokine of 
the T helper cell subset, Th17, has been indicated in 
the development of numerous inflammatory, 
autoimmune diseases, tumors, and in host defense 
against bacterial and fungal infection [16]. Besides 
Th17 cells, γδ T cells and macrophages are capable 
to produce IL-17 [21], [22], [23], [24], [25]. IL-17 can 
promote recruitment of macrophage and induce their 
cytokine/chemokine production, and thus capable of 
mediating a link between acquired and innate 
immunity, specifically, T cell and macrophage 
functions [17], [18]. 
Another modification of TAMs was the 
multinucleated giant cells (MGCs) which were often 
associated with PTC. There existed relatively few 
studies of MGCs in histology sections of PTCs. 
Probably these cells are formed in response to 
degenerative tumor areas and to abnormal colloid 
productions in PTC [19]. The prognostic significance 
of MGCs in PTC is uncertain. MGCs can be rarely 
found in follicular or anaplastic TC or in some 
inflammatory thyroid diseases as Hashimoto’s, De 
Quervain thyreoiditis [20], [21]. In the current study, 
we evaluated cases of PTC for the presence of 
macrophages, and estimated CD68
+ 
TAMs density
 
in 
tumor stroma, margin and the surrounding thyroid 
tissue. We assessed also MGCs. Macrophages and 
MGCs density were correlated with clinicopathologic 
parameters including patient’s age at diagnosis, tumor 
stage, grade of differentiation, extrathyroidal 
extension, capsule and vascular invasion to assess 
the possible prognostic significance of TAMs and 
MGCs in PTC. 
 
 
Material and Methods 
 
Tumour samples 
A series of 56 PTC cases has been retrieved 
from the Archives of the University Hospital in Stara 
Zagora, Bulgaria. The group of patients with PTC, 
include cases with lymph node metastases (n = 2 
(2.9%)) and without metastases (n = 0). The mean 
follow-up of 152.58 months; range from 1.64 to 197.07 
has been done. PTC tumors are presented as 1 cm/1 
cm or less in diameter and larger than 1 cm. There 
are 9 (16.7%) men and 47 (83.3%) women with age 
ranging from 22 to 81 years (mean 53.28 ± 13.756). 
Among the 56 PTC studied, 6 are ≤ 1 cm in diameter, 
and 50 tumors are larger. According to AJCC 
classification [22], 30 of the patients (53.6%) are in 
stage I, 18 of the patients (32%) are in stage II, 8 of 
the patients (14.4%) are in stage III, and no patients 
are in stage IV of the disease. For the statistical 
analysis cases were united I-II stage (Table 1). 
Table 1: Correlation between clinic-pathological factors and 
density of multinucleated giant cells MGCs in tumor stroma 
Parameters № 
Mgcs N (%) 
Non/few 
Mgcs N (%) 
Many 
P value 
Age  
< 53,28 
> 53.28 
 
30 
26 
 
21 (70.00) 
14 (53.8) 
 
9 (30.00) 
12 (46.2) 
 
 
0.213 
Gender 
Male 
Female 
 
9 
47 
 
7 (77.8) 
28 (59.6) 
 
2 (22.2) 
19 (40.4) 
 
 
0.301 
Pt classification 
T1-T2 
T3-T4 
 
50 
6 
 
34 (68.0) 
1 (16.7) 
 
16 (32.0) 
5 (83.3) 
 
0.014 
Lymph node metastases 
Yes 
No 
 
2 
54 
 
1 (50.00) 
34 (63.00) 
 
 
1 (50.00) 
20 (37.00) 
 
0.710 
Ptnm stage 
I = II 
III 
 
48 
8 
 
33 (68.8) 
2 (25.00) 
 
15 (31.3) 
6 (75.0) 
 
 
0.018 
Capsule invasion 
No 
Presence 
Presence of capsule 
invasion but without 
mgcs 
 
8 
34 
14 
 
5 (62.5) 
24 (70.6) 
- 
 
3 (37.5) 
10 (29.4) 
- 
 
 
0.656 
 
*X
2
-test; ** Values in bold italic shown (border) importance. 
 
The study protocol has been approved by the 
Research Ethics Committee of University Hospital 
Stara Zagora. 
All samples has been fixed in formalin and 
embedded in paraffin. Clinical data has been collected 
from the pathology reports, clinical files and from 
Oncology Dispensary. H & E slides are retrieved from 
the archives and they have been reviewed 
independently by two pathologists (MG and KI) and 
the tumors are classified using the WHO criteria [23]. 
Cases with doubtful PTC features are excluded. 
 
Immunohistochemistry 
Immunohistochemical staining was performed 
using streptavidin-biotin technique as previously 
described [24]. Briefly endogenous peroxidase was 
blocked was blocked with 3% hydrogen peroxidase in 
methanol for 10 min. Slides were incubated over night 
at room temperature with primary antibodies as 
followed: Anti-CD68 antibody Clone KP11 M0814 
were ready-to-use produced from DAKO, Glostrub, 
Denmark. After washing three times in PBS, the slides 
were incubated with DAKO-REALTM En-VisionTM 
detection system (DAKO) for 60 min, then visualized 
with diaminobenzidine and counterstained with 
Mayer’s hematoxylin. 
 
Double immunofluorescence for detection 
 of CD68 and IL-17 
For double immunoﬂuorescent procedure, 
sections were incubated in a primary antibody cocktail 
against ghrelin (Monoclonal mouse anti-human 
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antibody CD68 macrophagesClone KP11 M0814 
DAKO, Denmark 1: 50 and rabbit anti-human antibody 
IL-17 Clone sc-7927 Santa Cruz Biotechnology, USA 
1: 100) in a humidified chamber for 1 h at room 
temperature. Then the sections were washed three 
times in PBS, pH 7.4. After that the sections were put 
in a mixture of secondary antibodies: anti-rabbit IgG 
(WHOLE MOLECULE) TRITC conjugate antibody 
(T5268, Sigma-Aldrich Inc.) and anti-mouse IgG 
(WHOLE MOLECULE) FITC conjugate antibody (F 
9006 Sigma-Aldrich, Inc.) for 1 h at room temperature 
in a dark chamber, sealed with coverslip with 
PBS/glycerol solution was used.  
 
Figure 1: CD68 positive macrophages – MGCs, marked in green 
color- co-localization (x 200) 
 
Control sections were processed as described 
above. Sections were examined under ﬂuorescence 
microscope (Leica DM2500, Germany). Images were 
analyzed using LAS Leica Microsystems CMS GmbH 
software. CD68 were colored in green and IL-17 in red 
color (Figure 1 and Figure 2). 
 
Figure 2: IL-17 positive macrophages – MGCs, marked in red color- 
co-localization (x 200) 
 
Macrophage and MGCs counting  
A single pathologist (MG), who was blinded to 
the clinical assessments of each case, scored the 
cases by counting, the number of CD68 TAMs in five 
independent fields in the tumor and in the invasive 
front under a 400 x magnification. CD68
+ 
cell counts 
were expressed as the mean ± standard deviation. 
Slides for the presence of MGCs [18] certain 
strict histological criteria were employed (Figure 3): 
1. MGCs were situated in the lumina of 
tumor cystic spaces 
2. MGCs have glossy dense eosinophilic 
cytoplasm 
3. MCGs have at least three nuclei 
A semi quantitative assessment was as 
followed: 0 MGCs per slide = none; 1-2 MGCs per 
slide = few; ≥ 3 MGCs per slide = many.  
 
Figure 3: MGCs situated between papillae and next to the colloid 
(H&E х 100) 
 
Statistical analysis 
The SPSS 16.0 program for Windows was 
used for statistical analysis. The chi-squared test and 
Fisher’s exact test were used to compare the 
immunohistochemical staining and the 
clinicopathological parameters. ANOVA, Student-t-
test, Mann-Whitney U test and Kruskal-Wallis test 
were applied for comparing the continuous variables 
depending on the normality of the distribution. 
Correlations were tested by Spearmen and Person 
tests. The accepted level of significance was set at p 
< 0.05. 
 
 
Results 
 
In PTC cases a few of CD68
+ 
TAMs were 
observed in cystic spaces in the tumour in close 
connection with the colloid. These CD68
+ 
TAMs were 
oval with one nucleus (Figure 4a) (and would be 
interpreted as M1 in morphology) and some MGCs 
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having many nuclei and CD68
+
 cytoplasm (Figure 4b). 
In some PTCs MGCs were few (Figure 4c) or many 
(Figure 4d). MGCs were situated in between papillae 
and next to the colloid. 
a)
 
b)
 
c)
 
d)
 
Figure 4: 4а) CD68-positive macrophages М1 with oval form (х 
100); 4b) CD68- positive macrophages - MGCs (х 200); 4c) CD68- 
positive macrophages – MGCs - “few” (х 200); 4d) CD68- positive 
macrophages – MGCs - “many” (х 100) 
 
A statistically significant correlation was 
established between PTC patients in III stage, 
containing many MGCs, and PTC in I and II stage, 
with many MGCs. Eighty percent of patients in III 
stage showed many MGCs in comparison with 
patients in I and II stage, where many MGCs were 
found only in 21.1% (2 = 6.189, p = 0.013). 
 
 
Discussion 
 
Ryder at al., 2008 found that high density 
TAMs correlated with decrease cancer related survival 
in high-grade thyroid cancer (ATCs) and PDTC. 
Increased TAMs in PDTC were associated with 
capsular invasion and extrathyreoidal extension. 
However due the overall benign prognosis of PTC, the 
role of TAMs was not fully examined and understood. 
Higher TAMs density was most significantly 
associated with lymph node metastases and with 
advanced tumor stage (III-IV) in PTC [25]. Other 
investigators had found larger PTCs had high density 
TAMs [4]. Fiumara et al., 1997 [3], described a 
negative association between neoplastic cell 
phagocytosis by macrophages and tumor vascular 
invasion and distant metastases. However these 
authors mainly focused on macrophage phagocytosis 
and on the role of immune system in thyroid cancer 
development. In our study we focused investigation on 
increased TAMs density and PTC 
clinicomorphological parameters, while the increased 
TAMs density and TGF-β1signalling pathway proteins 
we analyzed in previous study [26]. 
CD68+ TAMs were investigated in some 
thyroid malignancies. (Ryder et al., 2008) investigated 
33 patients with WDTC (19 PTC), 13 patients with 
(FVPTC) and one with OC. They had found that the 
number of TAMs was < 5 (0.28 mm
2
) in most WDTC 
(34 patients) and > 10 (0.28 mm
2
) in less cases (9), 
and found no statistical correlation between presence 
of TAMs and extra thyroidal extension, capsular 
invasion and vascular invasion. We used CD68 
antibody to identify TAMs in PTC (or M2 
macrophages) since it was found that it is a universal 
marker for both types of macrophages (M1 and M2) 
[6], [9], [15]. Only the intracytoplasmic expression of 
IL-10 and IL-12 in TAMs could successfully 
differentiate two macrophage phenotypes [20]. We 
used CD68 staining in order to count TAMs in PTC 
ant to compare its number with that found by other 
investigators. Our TAMs numbers were that received 
by others in PTC [22], [26]. 
 
MGCs 
Multinucleated Giant cells or MGCs are found 
in thyroid diseases such as Hashimoto’s, De 
Quervains or in follicular or anaplastic thyroid cancer 
[23], [27]. In the recent years MGCs are often 
associated with PTC [18]. The results of our study 
indicated that MGCs can be found in (n= 56) of PTC 
cases similarly to previous reports [14]. MGCs were 
found in less WDTCs (27%) by Ryder M et al., 2008 
and in PTCs by Qing et al., 2012. We found for the 
first time that there was a definite prognostic 
significance to having “many” MGCs in PTC. In our 
study ‘”many” MGCs were statistically significantly 
correlated to the advanced tumor stage (III). Other 
authors detected that many MGCs in PTC were more 
likely associated with extrathyreoidal extension and 
greater tumor size (over stage III) in PTC was 
reported by [17], [19], [21]. 
Guitar et al., examined 76 cases of PTC and 
found MGCs in 46% (35/76). Tabbara et al., found in 
all (10 cases PTC-100%). MGCs in 63% of cases of 
FVPTC and in 7 of follicular adenoma. Other 
investigators using CD68 ICH found that TAMs (or 
MGCs-phagocytes) correlated with high lymphocyte 
and DCs, these patients had significantly less 
vascular invasion and remote metastasis [3]. The 
authors supposed that TAMs might activate the host 
immune response to cancer cells. To our knowledge, 
TAMs are plastic cells and they might act as tumor 
suppressors [9] by secreting IL-12 and have M1 
phenotype in answer to Th1 cytokines or tumor 
promoters by secreting IL-10 and answering to Th2 
cytokines. 
MGCs were considered to be of histiocytic 
origin [14], [18]. Our contribution to MGCs cytoplasmic 
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staining is that MGCs are mainly CD68
+
, CD123
+
 and 
thyroglobulin positive (having ingested colloid) [18]. 
Th17 cells and M1/M2 macrophages, these immune 
cells potentially function as a “double-edge” sword 
within the tumor microenvironment to enhance both 
anti-tumor immunity and inflammatory responses [16]. 
Our study demonstrates that the increased density of 
MGCs is associated with advanced stage of PTC, and 
therefore with tumor progression and that cases of 
PTC should be carefully screened for their presence. 
Our opinion is that tumor-associated macrophages 
are plastic cells that after recruitment in tumor 
microenvironment change their phenotype from M1 to 
M2 and so take part in the complex regulation of 
tumor regression and of tumor growth and 
progression. They are key component inflammatory 
circuits that organize adaptive immune response and 
angiogenesis-and promote tumor development. 
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